中国药房2026，Vol.37Issue(11)：1457-1461,5.DOI:10.6039/j.issn.1001-0408.2026.11.13
达格列净治疗左心疾病相关性肺动脉高压的疗效及预后观察
Clinical effects and prognostic observation of dapagliflozin in patients with pulmonary hypertension associated with left heart disease
摘要
Abstract
OBJECTIVE To evaluate the clinical efficacy of dapagliflozin in patients with pulmonary hypertension associated with left heart disease(PH-LHD)and its effect on prognosis,and to provide evidence for its clinical application.METHODS A total of 135 hospitalized patients with PH-LHD admitted to Wuxi No.2 People's Hospital from January 1,2023 to June 30,2025 were retrospectively included.According to the treatment regimen,the patients were divided into a control group(74 cases,receiving conventional treatment)and a dapagliflozin group(61 cases,receiving dapagliflozin in addition to conventional treatment).Blood pressure[systolic blood pressure,diastolic blood pressure,and pulmonary artery systolic pressure(PASP)],echocardiographic cardiac function parameters[cardiac output,cardiac index,left ventricular ejection fraction(LVEF),right ventricular ejection fraction(RVEF),left atrial diameter,and left ventricular wall thickness],inflammatory factors[interleukin-6(IL-6)and high-sensitivity C-reactive protein(hs-CRP)],brain natriuretic peptide(BNP),and 6-minute walking distance(6MWD)were compared between the two groups before treatment and after 12 weeks of treatment.All-cause mortality and the frequency of rehospitalization due to worsening heart failure during follow-up were also compared.RESULTS After 12 weeks of treatment,systolic blood pressure,diastolic blood pressure,PASP,left atrial diameter,IL-6,hs-CRP,and BNP levels were significantly decreased or shortened in both groups,while cardiac index and 6MWD were significantly increased or prolonged compared with those before treatment(P＜0.05).Cardiac output in the dapagliflozin group was significantly increased compared with that before treatment(P＜0.05).Systolic blood pressure,PASP,left atrial diameter,IL-6,hs-CRP,and BNP levels in the dapagliflozin group were significantly lower or shorter than those in the control group,while cardiac output,cardiac index,and 6MWD were significantly higher or longer than those in the control group(P＜0.05).There were no statistically significant differences in LVEF,RVEF,or left ventricular wall thickness between the two groups(P＞0.05).The median follow-up times in the control group and dapagliflozin group were 17.9 months and 17.3 months,respectively.During follow-up,all-cause mortality in the dapagliflozin group was lower than that in the control group,but the difference was not statistically significant(P＞0.05);the frequency of rehospitalization due to worsening heart failure was significantly lower than that in the control group(P＜0.05).CONCLUSIONS On the basis of conventional treatment,the addition of dapagliflozin can further reduce pulmonary artery pressure,inflammatory factor levels,and BNP levels in patients with PH-LHD,improve some cardiac function-related parameters and exercise tolerance,and reduce the frequency of rehospitalization due to worsening heart failure.关键词
达格列净/左心疾病/肺动脉高压/肺动脉收缩压/心功能/预后/炎症因子Key words
dapagliflozin/left heart disease/pulmonary hypertension/pulmonary artery systolic pressure/cardiac function/prognosis/inflammatory factors分类
医药卫生引用本文复制引用
李录,邱荣荣,董丰..达格列净治疗左心疾病相关性肺动脉高压的疗效及预后观察[J].中国药房,2026,37(11):1457-1461,5.基金项目
江苏省自然科学基金项目(No.202408011079) （No.202408011079）
